9
Recognition Of Team Science
Faculty Appointments, Promotions and Titles at The Geisel School of Medicine at Dartmouth
“Recognition by peers as an investigator whose work has been instrumental in promoting significant advances in her/his field of inquiry, inclusive of basic research, clinical research, pedagogy and health care delivery science. Hallmarks of recognition include both those made as an individual and those made as part of a larger, cooperative team.”
Dartmouth Cluster Initiative(e.g., “Big Data”)
“Solutions, breakthroughs, and advances often arise from collaborative efforts that transcend the traditional boundaries of academic disciplines. The cluster initiative, through faculty collaboration and targeted hiring, will provide the critical mass and spectrum of expertise necessary to shape and advance the understanding of complex problems, emerging issues, and future societal challenges.
The initiative will establish cohorts of scholars focused on new intellectual themes or questions that cut across disciplines, departments, and schools.”
Use of Developmental Funds
Programs
CCSG Supported
Number of recruitments supported
Number of CCSG Pilot Awards
Cancer Control 1 7Cancer Epidemiology 3 2Molecular Therapeutics 1 11Cancer Mechanisms 1 1Cancer Imaging and Radiobiology 0 6Immunology and Cancer Immunotherapy
0 4
Totals 6 31Value of peer –reviewed grants for these PIs or as a consequence of pilots
$6,565,802
$16,307,274
Ratio: Peer-reviewed grants/CCSG investment 21:1 23.7:1
CCSG Developmental Funds
Budgeted Uses 5y TotalPilot Projects $687,853New Faculty $315,000Shared Resources $60,000Technology/Methodology $10,000
Pilot Projects
• NCCC (Prouty): $250,000
• ACS Institutional Grant: $150,000
• Hopeman Cancer Clinical & Population Science: $200,000
• Cancer Nanotechnology: $60,000
• Cancer Comparative Effectiveness
• Cancer Program Projects LOIs
• LOIs for Foundation Cancer Proposals: V Foundation, Komen
New Shared Resources and Services: Trace Elements, geospatial Equipment Purchases: 9T MRI, Neogene sequencing platforms
Programs CC CE CM MT CIR ICI
Shared Resource
Biostatistics X X X X X X
Trace Elements X X X X X
Genomics and Mol. Biol. X X X X X
Bioinformatics X X X X X X
Immune Monitoring and FC X X X X X X
Clinical Pharmacology X X X X
Irrad.,PreClin. Imag., Micrscpy. X X X X X
Pathology X X X X X X
Transgenics & Gen. Constructs X X X X
Use of Shared Resources
Shared Resources add Value to NCCC
Early Phase Study Program Process
2008 2012 2013 2014
Protocol Specific Research Support Early Phase Clinical Research Support
LoI Process for
Early Phase Clinical Research
LoI Process for
Early Phase Clinical Research
Formalize Early Phase Trial
Clinical Oncology Group
Bench To/from Bedside
Molecular TumorBoard
DH Genetic Research Biobank
NCCC Strategic Plan 2012-2017 41st Year
An NCI-Designated Comprehensive Cancer Center MISSION, VISION, and VALUES
Research Care & Treatment Prevention Education
Innovate to control cancer through research Guide informed decision making by patients and families,
and deliver integrated patient care Improve population health by reducing environmental risk, lifestyle intervention and high value screening
Contribute to a sustainable health system by training scientists and doctors in oncology and patient-centered
care
Basic Science & Translation Recognition of the essential value of innovative partnerships between clinical providers and research scientists to improve cancer treatment
Population Health & Care Commitment to advance the field: innovation in clinical practice and the technology for high value research
People & Resources Accountability for best uses of institutional resources in research, treatment, prevention, and education
PERFORMANCE INDICATORS Clinical Trials
Patients Accrued to Trials 2012 - 6% 2014 % 2017 ___% Trials Closed w/ Attained Target Accrual 2012 ___% 2014 ___% 2017 ___% Number of D-studies opened annually 2012 - 20 2014 ____ 2017 ____
Completed Quality Improvement Projects Pathway Compliance Tumor Board Case Presentations
Hire New Faculty 2012 – 2013 – 10 faculty appointments 2014 - 2015 2016 - 2017
Shared Resources Provide centrally organized capabilities in 2 new Shared Resources 2014 Registries 2016 Survey Research Increase use or clientele in Shared Resources 2012 _____ 2017 _____
End of Life Patients with Advance Directives 2012 ___% 2014 ___% 2017 ___ % Documentation of End of Life Discussions 2012 ___% 2014 ___% 2017 ___ %
Increase Prouty Funding 2012 $2.6MM 2014 $3.0MM 2017 $3.5MM
Research Impact Total cancer-related publications 2012 – 426, 2014 ____ 2017 ____ Cancer-related in high-impact journals 2012 ___ 2014 ____ 2017 ____ Total of inter-programmatic collaborative publications 2012 - 47, 2014 ____ 2017 ___ Total of intra-programmatic collaborative publications 2012 – 121, 2014 ____ 2017 ___
Translation of Prevention Findings to Catchment Area # of citizens involved
Diet and Obesity 2012 ___ 2014 ____ 2017 ____ Smoking 2012 ___ 2014 ____ 2017 ____ Sun Safety 2012 ___ 2014 ____ 2017 ____ Screening 2012 ___ 2014 ____ 2017 ____
Peer-Reviewed Funding NIH-approved (incl. NCI) 2012 - $45.8MM 2014 ____ 2017 ____ NCI 2012 - $27.2MM 2014 ____ 2017 ____ Total – all sources 2012 - $61.7MM, 2014 ____ 2017 ____
Scientists in Tumor Boards 2012 - 3 in 14_ tumor boards 2014 ___ in ___ tumor boards 2017 ___ in ___ tumor boards
Improve Patient Experience Willingness to recommend to a friend 2012 ___% 2014 ___% 2017 ___% Patient & Family Services Programs - # of people 2012 ___ 2014 ____ 2017 ____
Pilot Funding for Research Develop Director’s Pilot Funding 2012 - 5, 2014 ____ 2017 ____ Increase Prouty Pilot funding grants 2012 - 7, 2014 ____ 2017 ____ Increase ACS pilot grants 2012 - 5, 2014 ____ 2017 ____
Advance Scientific Discovery Translate Scientific Discovery Lead the Nation in Cancer
Prevention & Health Promotion Deliver Patient-Centered Care Promote Regional Leadership Steward Resources
1a. Improve communication mechanisms between investigators and clinicians to
promote translational oncology
2a. Expand research resources to support translational and clinical science
3a. Use NCCC discoveries about personal and environmental risk factors to reduce
cancer risk for communities
0a. Define specific populations and achieve measurable advancement in their health status
by providing high value health care
5a. Communicate NCCC findings to inform public health policy on a regional and national level
6a. Focus on strengths in areas most likely to impact cancer in humans
1b.Encourage team science to promote multidisciplinary approaches
2b.Provide Cancer Center resources to remove barriers to conducting Dartmouth investigator-
initiated clinical translational trials
3b..Use population based research in cancer control to inform and optimize
primary care practices
0b. Achieve seamless coordination within NCCC, among external partners, making us the high-value health system of choice for our region
based on a Culture of Caring
5b.Network NCCC providers to partner with region-wide community-based services
6b.Facilitate communication among investigators and promote faculty
development to maximize scientific discovery .
1c.Encourage innovative approaches to resolve key questions in basic science,
clinical science, and population science to affect public health policy.
2c.Hire Strategically to support translational research
3c. Discover novel approaches to prevent or control cancer development
0c.. Use quality and safety metrics, health delivery science, and comparative effectiveness
to optimize patient outcomes
5c.Use NCCC’s specialized services and capabilities to provide region wide access to the
best cancer health care
6c.Optimize communication to increase awareness of NCCC expertise and services
Center VisionStrategic Goals
Enhance our translational focus and disseminate trials regionally by hiring 2 physician investigators
Discover new imaging strategies and incorporate imaging research into a broader spectrum of research by utilizing the Surgical Innovation Center and Advanced Imaging Center
Develop anti-VISTA therapies by expanding clinical immunotherapy group
Improve cancer outcomes in our catchment area by expanding our behavioral research.
Address emerging issues in cancer care delivery by comparative effectiveness research through increased interaction with TDI
Expand ongoing efforts to build global health initiatives by supporting pilot grants in this area.
Plans for Future Use
Pilot Projects• Translational• Collaborative• Interventional• Relevance to Strategic
Plan
Recruitment (Current)• Cancer Control /
Tobacco Policy• Biostatistics• Quantitative
Biomedical Sciences• Cancer Mechanisms• Early Phase Clinical
Development• Cancer
Immunotherapy
